Xtandi™ (Enzalutamide) Authorised In The European Union (EU) For Advanced Prostate Cancer

Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castrationresistant prostate cancer whose disease has progressed on or after docetaxel therapy[1] Astellas Pharma Europe Ltd., the European Headquarters of Tokyobased Astellas Pharma Inc. (TSE:4503), and Medivation, Inc...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news